


TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		Attorney's Docket No. 288748.0003
		U.S. Application No. Not Yet Known 09/831553
International Application No. PCT/GB99/03666	International Filing Date 05 November 1999 (05.11.99)	Priority Date Claimed 13 November 1998 (13.11.98)
Title of Invention: PROCESS FOR PREPARING ORAL CALCIUM COMPOSITIONS		
Applicant(s) For DO/EO/US: Jan Yngvar PIENE and Dina Dogger SCHMIDT		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(l). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a) <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b) <input type="checkbox"/> has been transmitted by the International Bureau. c) <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> A copy of the International Search Report. (PCT/ISA/210). 8. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a) <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b) <input type="checkbox"/> have been transmitted by the International Bureau. c) <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d) <input checked="" type="checkbox"/> have not been made and will not be made. 9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 10. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 13. to 20. below concern other document(s) or information included: 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input type="checkbox"/> Certificate of Mailing by Express Mail. 20. <input checked="" type="checkbox"/> Other items or information a) <input type="checkbox"/> Copy of Notification of Missing Requirements. b) <input checked="" type="checkbox"/> Itemized receipt page c) <input checked="" type="checkbox"/> Serial number post card. d) <input checked="" type="checkbox"/> This application is a continuation-in-part of International Application No. PCT/GB99/03666, filed on November 5, 1999, which claims the benefit of GB 9825033.5, filed on November 13, 1998 e) <input type="checkbox"/> _____ f) <input type="checkbox"/> _____ g) <input type="checkbox"/> _____		

U.S. Application No. Not Yet Known 09/831553		International Application No. PCT/GB99/03666		Attorney Docket No. 288748.0003	
---------------------------------------------------------------	--	--------------------------------------------------------	--	-------------------------------------------	--

21. The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;"><input type="checkbox"/> Neither international preliminary examination fee nor international search fee paid to USPTO; International Search Report not prepared by the EPO or JPO</td> <td style="width: 40%; text-align: right;">\$ 1,000.00</td> </tr> <tr> <td><input checked="" type="checkbox"/> International preliminary examination fee not paid to USPTO; International Search Report prepared by EPO OR JPO</td> <td style="text-align: right;">\$ 860.00</td> </tr> <tr> <td><input type="checkbox"/> International preliminary examination fee not paid to USPTO; international search fee paid to USPTO</td> <td style="text-align: right;">\$ 710.00</td> </tr> <tr> <td><input type="checkbox"/> International preliminary examination fee paid to USPTO; all claims did not satisfy provisions of PCT Article 33(1)-(4)</td> <td style="text-align: right;">\$ 690.00</td> </tr> <tr> <td><input type="checkbox"/> International preliminary examination fee paid to USPTO; all claims satisfied provisions of PCT Article 33(1)-(4)</td> <td style="text-align: right;">\$ 100.00</td> </tr> </table>					<input type="checkbox"/> Neither international preliminary examination fee nor international search fee paid to USPTO; International Search Report not prepared by the EPO or JPO	\$ 1,000.00	<input checked="" type="checkbox"/> International preliminary examination fee not paid to USPTO; International Search Report prepared by EPO OR JPO	\$ 860.00	<input type="checkbox"/> International preliminary examination fee not paid to USPTO; international search fee paid to USPTO	\$ 710.00	<input type="checkbox"/> International preliminary examination fee paid to USPTO; all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$ 690.00	<input type="checkbox"/> International preliminary examination fee paid to USPTO; all claims satisfied provisions of PCT Article 33(1)-(4)	\$ 100.00	Calculations <i>PTO USE ONLY</i>
<input type="checkbox"/> Neither international preliminary examination fee nor international search fee paid to USPTO; International Search Report not prepared by the EPO or JPO	\$ 1,000.00														
<input checked="" type="checkbox"/> International preliminary examination fee not paid to USPTO; International Search Report prepared by EPO OR JPO	\$ 860.00														
<input type="checkbox"/> International preliminary examination fee not paid to USPTO; international search fee paid to USPTO	\$ 710.00														
<input type="checkbox"/> International preliminary examination fee paid to USPTO; all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$ 690.00														
<input type="checkbox"/> International preliminary examination fee paid to USPTO; all claims satisfied provisions of PCT Article 33(1)-(4)	\$ 100.00														
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$860.00													
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date 37 CFR 1.492(e).		\$0.00													
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$0.00											
Total Claims	21 - 20 =	1	x \$18.00	\$18.00											
Indep. Claims	2 - 3 =	0	x \$80.00	\$0.00											
Multiple Dependent Claims (if applicable)			\$270.00	\$0.00											
TOTAL OF ABOVE CALCULATIONS =		\$878.00													
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28)		\$0.00													
SUBTOTAL =		\$878.00													
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$0.00													
TOTAL NATIONAL FEE =		\$878.00													
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).		\$0.00													
TOTAL FEES ENCLOSED =		\$878.00													

☒ A check in the amount of \$ 878.00 to cover the above fees is enclosed.
☐ Please charge Deposit Account No. 50-1656 in the amount of \$ 0.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
☒ The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to **Deposit Account No. 50-1656**. A duplicate copy of this sheet is enclosed

SEND ALL CORRESPONDENCE TO: John W. Ryan WILMER, CUTLER & PICKERING 2445 M Street, N.W. Washington, DC 20037-1420	 dated May 11, 2001 John W. Ryan, Reg. No. 33,771 202-663-6446 202-663-6363 (facsimile)
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

09/831553

JC08 Reg'd PCT/PTO 11 MAY 2001

In The United States Patent and Trademark Office

Applicant : Jan Yngvar Piene and Dina Dogger Schmidt
Appl. No. :
Filed: : Herewith
Title : PROCESS FOR PREPARING ORAL CALCIUM
COMPOSITIONS

Grp./A.U. :
Examiner :

Docket No. : 288748.0003

Honorable Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the above-identified application as follows:

In the specification:

Please insert the following language as the first sentence of the specification following the title preferably as a separate paragraph (37 CFR 1.78(a)):

"This application is a continuation-in-part of International Application No. PCT/GB99/03666, filed on November 5, 1999, which claims the benefit of GB 9825033.5, filed on November 13, 1998."

In the claims:

Please cancel claims 15-21.

Please amend the claims as follows:

4. (Amended) A process as claimed in claim 3 wherein said calcium compound makes up 68 to 80% wt. of said first granulate.

5. (Amended) A process as claimed in claim 3 wherein said calcium compound makes up 60 to 95% wt. of said second granulate.

6. (Amended) A process as claimed in claim 3 wherein in step (i) the same material is used as said diluent and as said binder.

7. (Amended) A process as claimed in claim 3 wherein said water-soluble diluent comprises at least one sweetener.

9. (Amended) A process as claimed in claim 9 wherein said water-soluble diluent makes up 70 to 96% wt. of the total weight of said water-soluble diluent and said water-soluble binder in said first granulate.

10. (Amended) A process as claimed in claim 3 wherein said water-soluble binder is selected from celluloses, polysaccharides, maltodextrin, inulin and polyvinylpyrrolidone.

11. (Amended) A process as claimed in claim 3 wherein said water-soluble binder is a polyvinylpyrrolidone.

12. (Amended) A process as claimed in claim 3 wherein said first granulate has a particle size distribution of $D(V, 0.1) = 15-21 \mu\text{m}$, $D(V, 0.5) = 70-120 \mu\text{m}$ and $D(V, 0.9) = 190-330 \mu\text{m}$.

13. (Amended) A process as claimed in claim 3 wherein a said further component is mixed with said first granulate, said further component being selected from: vitamin B₆, vitamin K, vitamin C, vitamin D, isoflavones, inulin, and oligofructose and mixtures of two or more thereof.

14. (Amended) A process as claimed in claim 3 wherein in step (ii) said calcium compound is also mixed with isoflavones.

REMARKS/ARGUMENTS

Claims 4-7 and 9-14 have been amended.

Claims 15-21 have been canceled, however we reserve the right to file a divisional application on these same claims.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

WILMER, CUTLER & PICKERING

Dated: May 11, 2001

John W. Ryan

John W. Ryan

Reg. No. 33,771

WILMER CUTLER & PICKERING

2445 M Street, NW

Washington, DC 20037-1420

(202) 663-6446

(202) 663-6363 (facsimile)

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claims 15-21 have been canceled.

Claim 4 has been amended as follows:

4. (Amended) A process as claimed in [any one of claims 1 to] claim 3 wherein said calcium compound makes up 68 to 80% wt. of said first granulate.

Claim 5 has been amended as follows:

5. (Amended) A process as claimed in [any one of claims 1 to 4] claim 3 wherein said calcium compound makes up 60 to 95% wt. of said second granulate.

Claim 6 has been amended as follows:

6. (Amended) A process as claimed in [any one of claims 1 to 5] claim 3 wherein in step (i) the same material is used as said diluent and as said binder.

Claim 7 has been amended as follows:

7. (Amended) A process as claimed in [any one of claims 1 to 6] claim 3 wherein said water-soluble diluent comprises at least one sweetener.

Claim 9 has been amended as follows:

9. (Amended) A process as claimed in [any one of claims 1 to 8] claim 3 wherein said water-soluble diluent makes up 70 to 96% wt. of the total weight of said water-soluble diluent and said water-soluble binder in said first granulate.

Claim 10 has been amended as follows:

10. (Amended) A process as claimed in [any one of claims 1 to 9] claim 3 wherein said water-soluble binder is selected from celluloses, polysaccharides, maltodextrin, inulin and polyvinylpyrrolidone.

Claim 11 has been amended as follows:

11. (Amended) A process as claimed in [any one of claims 1 to 10] claim 3 wherein said water-soluble binder is a polyvinylpyrrolidone.

Claim 12 has been amended as follows:

12. (Amended) A process as claimed in [any of claims 1 to 11] claim 3 wherein said first granulate has a particle size distribution of $D(V, 0.1) = 15-21 \mu\text{m}$, $D(V, 0.5) = 70-120 \mu\text{m}$ and $D(V, 0.9) = 190-330 \mu\text{m}$.

Claim 13 has been amended as follows:

13. (Amended) A process as claimed in [any one of claims 1 to 12] claim 3 wherein a said further component is mixed with said first granulate, said further component being selected from: vitamin B₆, vitamin K, vitamin C, vitamin D, isoflavones, inulin, and oligofructose and mixtures of two or more thereof.

Claim 14 has been amended as follows:

14. (Amended) A process as claimed in [any one of claims 1 to 13] claim 3 wherein in step (ii) said calcium compound is also mixed with isoflavones.

Process for preparing oral calcium compositions

5 This invention relates to a process for the manufacture of an orally administrable pharmaceutical composition containing a physiologically tolerable calcium compound, in particular a composition in tablet form.

10 Calcium carbonate tablets are used as a source of calcium, especially for patients suffering from or at risk of osteoporosis. Moreover calcium carbonate is used as an acid neutralizing agent in antacid tablets.

15 Calcium carbonate is used in such tablets since the calcium content of calcium carbonate is high, the calcium is presented in a form which can be taken up from the gastrointestinal tract, calcium carbonate is effective at neutralizing gastric acids, and calcium carbonate is a physiologically acceptable calcium
20 compound.

In such tablets, various binders, sweeteners and flavors are used in order to produce a tablet which is readily acceptable to the patient. Indeed many producers have sought to achieve improved patient
25 acceptability by formulating the tablets with such excipients in a "chewable" form. As a result, and since the daily recommended dosage is generally about 1000 mg calcium, the commercially available calcium tablets which commonly contain 500 mg calcium are relatively
30 bulky.

Examples of chewable calcium carbonate tablets are described in WO 96/09036 (Laboratoire Innothera) and in US-A-4446135 (Sterling Drug). The chewable calcium carbonate tablets described in these two patent
35 publications have a calcium carbonate content of about 50% or less by weight and for a 500 mg calcium dosage are therefore undesirably large.

The present invention is directed to a process by which this undesired bulk may be reduced, and in particular to a process by which a chewable calcium tablet may be produced with a calcium compound content in excess of 60% by weight.

Thus viewed from one aspect the present invention provides a process for the preparation of an orally administrable calcium composition, said process comprising the steps of:

- (i) obtaining a physiologically tolerable particulate calcium compound having a mean particle size in the range 3 to 40 μ m, having a crystalline structure and having a specific surface area of 0.1 to 1.2 m²/g, preferably 0.2 to 0.9 m²/g, especially 0.3 to 0.8 m²/g;
- (ii) mixing said calcium compound with a water-soluble diluent and an aqueous solution of a water soluble binder in a fluid bed granulation apparatus and drying the resulting mixture to produce a first granulate;
- (iii) optionally mixing said first granulate with one or more further components to produce a second granulate, preferably a granulate having a content of said calcium compound of at least 60% by weight; and
- (iv) optionally compressing said first or second granulate to form tablets.

The physical characteristics of the calcium compound used in the process of the invention are important in order that the fluid bed granulation stage should produce a first granulate having the desired characteristics. The calcium compound should be crystalline and have a mean particle size of 3 to 40 μ m, preferably 5 to 30 μ m. Preferably it should have a bulk density in the range of 0.2 to 1.5g/mL, more preferably 0.3 to 1.4g/mL, especially 0.4 to 1.3g/mL. The calcium compound is preferably an acid soluble compound, e.g. a compound poorly soluble or insoluble in water at pH7 but soluble in water at gastric pH values.

The upper particle size limit of $40\mu\text{m}$ is important in order to avoid a gritty mouthfeel in the final product. The lower particle size limit of $3\mu\text{m}$ is also important in order to avoid a feeling of stickiness on the teeth during chewing.

Crystallinity, in particular the possession of relatively smooth crystal surfaces and low specific surface area, is important for the achievement of effective and rapid wetting and granulation in the fluid granulation step of the process of the invention.

Specific surface area may be determined using apparatus such as the Carlo Erba Sorptomatic 1900.

The calcium compound may, for example, be selected from calcium carbonate, calcium lactate, calcium gluconate, calcium citrate, calcium glycerophosphate, calcium phosphate, calcium hydrogen phosphate (e.g. in tribasic, dibasic or monobasic forms, i.e. $\text{Ca}_3(\text{PO}_4)_2$, $\text{CaHPO}_4 \cdot 2\text{H}_2\text{O}$ and $\text{Ca}(\text{HPO}_4)_2 \cdot \text{H}_2\text{O}$), calcium glucuronate, calcium aspartate, calcium glucoheptonate and mixtures of two or more thereof. However, calcium carbonate, in particular in calcite form, is preferred due to its high calcium content, its ready availability, its cost, its well-documented absorption characteristics in humans, and its performance in the fluid granulation step of the process of the invention.

Especially, preferably calcium carbonate having individual or primary and cubic or pseudo-cubic shaped calcite crystals with smooth or even surfaces are used. Desirably such crystals are also transparent. Where the end product is for use as a medicine, it is also preferred that the calcium carbonate be a material precipitated according to Ph. Eur.

Examples of appropriate commercially available calcium carbonate include Merck 2064 (available from Merck, Darmstadt, Germany), Scoralite 1A and Scoralite 1B (available from Scora Watrigant SA, France), Super-Purity CaCO_3 and Medicinal Heavy CaCO_3 (available from

Shanghai Da Yu Biochemistry Co. Ltd., China), and
Pharmacarb LL (available from Crompton & Knowles,
Vineland, USA). Scoralite 1B and Scoralite 1A + 1B are
particularly preferred. Merck 2064 has a mean particle
5 size of 10 to 30 μ m, an apparent bulk density of 0.4 to
0.7 g/mL, and a specific surface area of 0.3 m²/g;
Scoralite 1A has a mean particle size of 5 to 20 μ m, an
apparent bulk density of 0.7 to 1.0g/mL and a specific
surface area of 0.6 m²/g; Scoralite 1A + 1B has a mean
10 particle size of 7 to 25 μ m, an apparent bulk density of
0.7 to 1.2 g/mL and a specific surface area of 0.35 to
0.8 m²/g; Scoralite 1B has a mean particle size of 10 to
30 μ m, an apparent bulk density of 0.9 to 1.3 g/mL and a
specific surface area of 0.4 to 0.6 m²/g; Medicinal Heavy
15 CaCO₃ has a mean particle size of 5 to 30 μ m, an apparent
bulk density of 0.9 to 1.3 g/mL and a specific surface
area of 0.8 m²/g; Super-Purity CaCO₃ has a mean particle
size of 10 to 30 μ m, an apparent bulk density of 0.9 to
1.2 g/mL and a specific surface area of 0.6 m²/g; and
20 Pharmacarb LL has a mean particle size of 5 to 30 μ m, an
apparent bulk density of 0.8 to 1.2 g/mL and a specific
surface area of 0.7 m²/g. The Pharmacarb LL calcium
carbonate however is not apparently a material
precipitated in accordance with Ph. Eur. and thus is
25 more preferred for production of end products which are
for use as dietary supplements or food products than
those which are for use as pharmaceuticals.

The calcium compound or mixture of calcium compound
preferably makes up 60 to 95% by weight of the second
30 granulate, and preferably provides a calcium content of
15 to 40%, more especially 20 to 35%, and still more
especially 25 to 30% by weight in the second granulate.

The calcium compound or mixture of compounds
preferably makes up 60.5 to 96%, more preferably 66 to
35 91% still more preferably 68 to 80% and most preferably
72 to 76% by weight of the first granulate.

The water-soluble diluent used in step (ii) of the

process of the invention is preferably a sweetener or a mixture of sweeteners, e.g. a polyol or a polysaccharide, more preferably a non-cariogenic sweetener. Examples of suitable diluents include sorbitol, xylitol, isomalt and mannitol, which are non-cariogenic. Neosorb P100T sorbitol, xylitol CM50 and isomalt PF are available commercially from Roquette Freres, Xyrofin and Palatinit respectively. Further examples of suitable saccharide-based diluents include sucrose, fructose and the maltodextrins (e.g. Lycatab DSH available from Roquette Freres). Especially preferred as diluents are the non-cariogenic oligosaccharides such as inulin and oligofructose. Inulin may be obtained by extraction from chickory root and is available under the trade name Raftiline from Orafiti SA, Tieren, Belgium. Oligofructose is obtained by partial hydrolysis of inulin and is available from Orafiti SA under the trade name Raftilose and from Beghin-Meiji Industries, Neuilly-sur-Seine, France under the trade name Actilight.

The diluent preferably makes up the major proportion, e.g. by 70 to 96%, more preferably 80 to 95%, still more preferably 85 to 94%, most preferably 90 to 92% of the total weight of diluent and binder in the first granulate.

The calcium compound and diluent (which, especially in the case of inulin, may be the same material as is used as the binder) are preferably blended before addition of the aqueous binder. The blending may conveniently be performed as a dry blending, for example using a blender with a rotating mixer arm, e.g. a blade. This ensures that any lumps are removed and achieves an intimate mixing of the calcium compound and the diluent. By way of example, a high speed mixer (e.g. Fielder PMA 25/2G) may be used operating at maximum speed for both the impeller and knife for two minutes; however any mill may be used to break up lumps in the mixture and indeed

the calcium compound and the diluent may be treated in this way separately to remove lumps before they are blended.

5 The water-soluble binder used in step (ii) of the process of the invention may be selected from known water-soluble pharmaceutical binders, e.g. it may be a soluble cellulose or polysaccharide or a polyvinylpyrrolidone or a mixture thereof. Preferably the binder is a polyvinylpyrrolidone, e.g. Kollidon K30,
10 Kollidon 90F or Kollidon VA64 which are available commercially from BASF. Inulin and maltodextrin may also be used as binders.

15 The binder is preferably used in aqueous solution at a concentration of 10 to 35% by weight, more especially 15 to 35%, preferably 25 to 30%, and particularly 27 to 29% by weight.

20 The fluid granulation step, step (ii) of the process of the invention, may be effected in any fluid granulation apparatus, e.g. a Glatt GPCG 3 fluid bed available from Glatt GmbH. The procedure preferably involves spraying the aqueous binder mixture onto the fluidized diluent/calcium compound mixture. Fluidization may be achieved by gas flow through the mixture or alternatively mechanically, e.g. by the use
25 of counter-rotating, interlocking paddles with horizontal rotational axes. The liquid sprayed is preferably at or near ambient temperature (e.g. 15 to 35°C, preferably 20 to 30°C, more preferably about 25°C) and the particulate onto which it is sprayed is again
30 preferably at or near ambient temperature (e.g. 15 to 35°C, preferably 20 to 30°C, more preferably about 25°C). The gas pressure of the spray chamber is conveniently ambient (e.g. 1 atmosphere). The spray rate may be
35 adjusted, according to batch size and component identities and concentrations, to optimize the mean particle size of the first granulate. However, for a 3kg solids batch, a spray rate of 30 to 50g/min may be

appropriate and a spray rate of about 40g/min is particularly preferred.

The granulate may be dried in a separate drier but preferably is dried in place in the fluidized bed mixer, e.g. using a heated gas (e.g. air) flow through the granulate. This can be effected while spraying of the binder solution is taking place or after spraying of the binder solution has been completed. Clearly if drying is effected during spraying it should be completed after spraying has stopped. Preferably a drying gas temperature of 60 to 90°C, more especially 65 to 75°C, in particular about 70°C is used. Particularly preferably drying is effected such that the granulate temperature reaches 40 to 50°C, especially about 43 to 45°C.

In this way a first granulate having a low water content, e.g. 1 to 5% by weight, preferably about 3%, may be produced and subsequently dried to a moisture content of about 0.1 to 0.5%, preferably 0.2% by weight, within an overall granulation and drying period of 15 to 45 mins, preferably 20 to 30 mins.

The first granulate preferably has a particle size distribution (as determined by Malvern particle size analysis) as follows:

$D(v, 0.1) = 15-21 \mu m$

$D(v, 0.5) = 70-120 \mu m$

$D(v, 0.9) = 190-330 \mu m$

Where the first granulate is to be mixed with further components before tableting, such further components will typically be one or more of the following: further active agents, e.g. vitamins, in particular vitamin D, especially vitamin D₃; effervescent agents; diluents; sweeteners; flavors; acidulants; and lubricants, e.g. hydrogenated fatty acids, polyethyleneglycol, sodium stearyl fumarate, stearic acid and salts thereof, for example magnesium stearate. When a further active agent is added, this should be at a therapeutically effective dosage. When

vitamin D is added, e.g. to produce a product suitable for treatment or prophylaxis of osteoporosis, this preferably is at a calcium to vitamin D ratio of 100 mg Ca: 30 to 150 IU Vitamin D, especially 100:35 to 100 IU, more especially 100:40 to 90 IU. Preferably the second granulate should be such as to be tabletable to produce tablets containing 500mg Ca and 200 to 250 IU or 400 to 450 IU vitamin D₃.

Where vitamin D is used, this may conveniently be vitamin D₂ (ergocalciferol) or more preferably vitamin D₃ (cholecalciferol). Dose units of the second granulate, e.g. tablets formed therefrom, preferably contain 250 to 1500mg Ca and 5 to 30µg vitamin D.

Vitamin D₃ is commercially available from Roche in a granular form which consists of vitamin D₃ in edible fats finely dispersed in a starch coated matrix of gelatin and sucrose with D,L-α-tocopherol added as an antioxidant. However, other dry powder or granulate forms of vitamin D may also be used.

A chewable tablet containing 500 mg calcium and 5 µg vitamin D₃ only contains 2.2 mg of the commercial quality of vitamin D₃ from Roche (100 CWS). This constitutes only 0.13% of the total weight of the tablet and one may thus anticipate problems with the homogeneity of vitamin D₃ in the tablet. A Malvern particle size analysis of the 100 CWS quality typically gives the following results for the particle size distribution: D(v, 0.1)=180-250 µm, D(v, 0.5)=240-300 µm and D(v, 0.9)=320-400 µm. It has been found desirable to sieve the vitamin D₃ on 60 mesh (250 µm) with a Russell vibrating sieve. This procedure will increase the number of vitamin D₃ particles per tablet and thus facilitate a more even and uniform distribution. In addition to this the sieving procedure will also eliminate all the coarse particles in the vitamin D₃ which also contribute to an inhomogeneous distribution.

Twenty consecutive batches of a chewable tablet

containing 500 mg calcium and 5 μ g vitamin D₃ have been produced which have utilized a sieved (< 60 mesh) vitamin D₃ with a mean particle size in the region of 203-217 μ m. All twenty batches comply with the requirements set in the European Pharmacopeia with respect to the uniformity of content of vitamin D₃ in the tablet.

Other active ingredients can be included in the compositions produced according to the invention. Examples include isoflavones, vitamin K, vitamin C, vitamin B₆ and oligosaccharides such as inulin and oligofructose. Isoflavones exhibit a weak oestrogenic effect and can thus increase bone density in post-menopausal women. Isoflavones are available under the trade name Novasoy 400 from ADM Nutraceutical, Illinois, USA. Novasoy 400 contains 40% isoflavones and will typically be used in an amount sufficient to provide 25 to 100 mg isoflavone/dosage. Isoflavones may be included in the second granulate; however as Novasoy 400 is a relatively cohesive powder it is preferred that it be included in the first granulate in order to ensure that it is uniformly distributed. Vitamin K (more especially vitamin K₁) may improve biochemical markers of bone formation and bone density and low concentrations of vitamin K₁ have been associated with low bone mineral density and bone fractures. Vitamin K₁ is available from Roche as Dry Vitamin K₁, 5% SD, a dry substance containing 5% vitamin K₁. Typically vitamin K₁ will be used in a quantity sufficient to provide 0.05 to 5 mg vitamin K₁/dosage. Vitamin C and vitamin B₆ (available from Roche, Takeda and BASF amongst others) function as co-factors in the formation of collagen, the main component of the organic matrix of bone. Vitamin C and vitamin B₆ will typically be used in quantities sufficient to provide 60 to 200 mg vitamin C/dosage and 1.6 to 4.8 mg vitamin B₆/dosage respectively. Oligosaccharides have been shown to facilitate and

increase calcium absorption and may typically be used in quantities sufficient to provide 0.3 to 5 g oligosaccharide/dosage. In general it is desirable that a total of at least 5g oligosaccharide is administered daily to facilitate calcium uptake and to obtain a pre-biotic effect.

Where an active component is used which forms a minor part of the overall granulate, e.g. vitamin D, it is general preferred to produce a premix of such a component and the first granulate before mixing the premix and the remaining required quantity of the first granulate. This ensures uniform distribution of the minor component in the second granulate.

The second granulate also preferably contains a flavor, e.g. a fruit flavor, in particular a lemon or orange flavor, in order to mask the chalky taste of calcium carbonate. The flavor may, for example, be a lemon or orange oil dispersed in a hydrogenated glucose syrup material or, alternatively, it may be any other stable flavor, e.g. one of the Durarome flavors available from Firmenich.

Extra sweeteners, e.g. artificial sweeteners such as aspartame, acesulfame K, saccharin, sodium saccharin, neohesperidine hydrochloride, taumatin and sodium cyclamate may be used to enhance the sweetness of the granulate.

Acidulants, e.g. anhydrous citric acid, malic acid, or any other organic acid with suitable organoleptic properties may be used in order to complement and enhance the flavour and sweetness of the dosage form.

Such extra components may be mixed in during the fluid granulation step of the process of the invention, but preferably they are mixed in with the first granulate in a separate dry mixing step, optionally after a sieving step to ensure homogeneous mixing.

When the granulate is to be tabletted, it preferably includes a lubricant, e.g. magnesium

stearate, stearic acid, hydrogenated fatty acids, sodium stearyl fumarate, PEG 6000 or PEG 8000. Magnesium stearate is generally preferred. Such a lubricant will generally make up 0.3 to 1.5%, particularly 0.35 to 1.0% by weight of the composition to be tabletted. The lubricant is preferably added in a final mixing step and mixed in for a brief time to prevent overmixing and subsequent lack of cohesion in the tabletted product.

Where the granulate is to be tabletted, this can be effected on conventional tablet presses. Preferably the tablet so produced will have a total weight of 500 to 3800mg, e.g. 500 to 3000 mg, more especially 1000 to 2500mg, most preferably 1500 to 2000mg. If desired however, the granulate (either the first granulate or the second granulate) may be used for other administration forms, e.g. powders, capsules, lozenges, coated tablets, etc. In general dose units (e.g. tablets or sachet contents) will contain 100 to 1000 mg Ca, especially 250 to 750 mg Ca, most preferably 450 to 550 mg Ca. The granulate is itself novel and forms a further aspect of the invention. Viewed from this aspect, the invention provides a granulate, preferably a tablettable granulate, comprising a fluid bed granulation granulate product of a physiologically tolerable calcium compound, a water-soluble binder and a water-soluble diluent, said calcium compound having a mean particle size in the range 3 to 40 μ m, having a crystalline structure and having a surface area of 0.1 to 1.2 m²/g.

The calcium compound for preparation of the granulate may, for example, be selected from calcium carbonate, calcium lactate, calcium gluconate, calcium citrate, calcium glycerophosphate, calcium phosphate, calcium hydrogen phosphate, calcium glucuronate, calcium aspartate, calcium glucoheptonate and mixtures of two or more thereof.

The water-soluble diluent included in the granulate

is preferably a sweetener or mixture of sweeteners, e.g. a polyol or a polysaccharide, more preferably a non-cariogenic sweetener. Examples of suitable diluents include sorbitol, xylitol, mannitol, sucrose, fructose, maltodextrin, inulin and oligofructose.

The water-soluble binder included in the granulate may be selected from known water-soluble pharmaceutical binders, e.g. it may be a soluble cellulose or polysaccharide or a polyvinylpyrrolidone or a mixture thereof. Maltodextrin and inulin may also be used as binders.

Other active ingredients can also be included in the granulate of the invention. Examples include vitamin B₆, vitamin K, vitamin C, vitamin D, isoflavones, inulin and oligofructose and mixtures of two or more thereof.

Viewed from a further aspect, the invention provides a physiologically tolerable particulate calcium compound having a mean particle size in the range 3 to 40 μ m, having a crystalline structure and having a surface area of 0.1 to 1.2 m²/g produced by the process of the invention.

Viewed from a still further aspect the invention provides an orally administrable calcium composition, preferably in tablet (e.g. compressed tablet) form, comprising a physiologically tolerable particulate calcium compound having a mean particle size in the range 3 to 40 μ m, having a crystalline structure and having a surface area of 0.1 to 1.2 m²/g, a water-soluble diluent, and a water soluble binder; e.g. calcium carbonate, sorbitol and PVP, and preferably also a sweetener, a flavour and a lubricant, e.g. aspartame, citrus oil and magnesium stearate. Especially preferably the composition is in the form of a tablet comprising 1250 \pm 10% parts by weight calcium carbonate, (e.g. as Scoralite 1A and/or 1B), 390 \pm 10% parts by weight sorbitol, and 36.4 \pm 10% parts by weight PVP, and

preferably each tablet contains $1250 \pm 10\%$ mg calcium carbonate.

The present invention makes it possible to reduce the amount of soluble diluent and binder in a chewable calcium tablet while sustaining the desirable chewability by the production of a highly porous granulate by fluid bed granulation using a calcium compound with a relatively high degree of crystallinity and with smooth faces to the crystals. This high degree of porosity, desirably 20 to 30%, results in the final chewable tablet having improved sensoric properties despite having a high calcium content. Such properties include improved dispersion in water and reduced stickiness during mastication.

The porosity of the granulate or tablet may be determined using mercury intrusion porosimetry (e.g. using a Carlo Erba Porosimeter 2000), and by helium adsorption, e.g. using an AccuPyc 1330 pycnometer to measure true density and a Geopyc 1360 envelope measuring apparatus. AccuPyc 1330 and Geopyc 1360 apparatus are available from Micrometrics. Mercury intrusion porosimetry is the more suitable of the two techniques for measuring the porosity of a granulate while both techniques can be used for measuring the porosity of a tablet.

Viewed from a further aspect the invention provides a tablet (e.g. a lozenge, chewable tablet or a effervescent tablet) comprising a compressed granulate according to the invention and containing: calcium carbonate; vitamin D₃; a lubricant; citric acid; and an oligosaccharide; and, optionally but preferably, polyvinylpyrrolidone.

The invention will now be described further with reference to the following non-limiting Examples and the accompanying drawings in which Figures 1 to 6 are scanning electron micrographs of six different grades of calcium carbonate and Figures 7A, 7B, 8A and 8B are

scanning electron micrographs of granulates prepared according to the invention at lower (Figs. 7A and 8A) and higher (Figs. 7B and 8B) magnification:

5 **EXAMPLE 1**

Preparation of First Granulate

 A binder solution is prepared containing 27.7% by weight of polyvinylpyrrolidone (Kollidon K30) in purified water. This is temperature-controlled at 20°C or more preferably 25°C before spraying.

 A batch of 74.5 parts by weight calcium carbonate (Scoralite 1B) and 23.3 parts by weight sorbitol (Neosorb P100T) is blended for two minutes using a high speed mixer (Fielder PMA 25/2G) set at maximum mixing speed. 3.0kg of this blend are then placed at 23-26°C in the mixer chamber of a Glatt GPCG3 fluid bed mixer.

 The polyvinylpyrrolidone solution is then sprayed onto the fluidized blend at a rate of 40g/min until a total of 280g of liquid has been added. Spraying is effected into air at an inlet temperature of 45°C and at ambient pressure.

 Air at 70°C is then passed through the sprayed granulate until it is dry (about 0.2% by weight residual moisture content). At this stage, the granulate temperature is about 44°C. The total duration of the spraying and drying stage is about 25 minutes.

 At the end of the drying stage the first granulate has the following properties:

30 mean particle size and distribution $D(v, 0.1) = 16 \mu\text{m}$,
 $D(v, 0.5) = 100 \mu\text{m}$, and $D(v, 0.9) = 284 \mu\text{m}$

 Bulk density: 0.73g/mL

 Porosity: 20-30%

 Flowability (Carrs index %) : 13

35 The mean particle size analysis is performed on a Malvern Mastersizer S long bench apparatus $D(v, 0.1)$, $D(v, 0.5)$, and $D(v, 0.9)$ give the particle sizes for which

10%, 50% and 90% of the particles by volume have sizes below the given values.

EXAMPLE 2

5 **Preparation and Tableting of Second Granulate**

4.4 parts by weight of sieved (< 60 mesh) Vitamin D₃ from Roche and 32 parts by weight of the first granulate are dry mixed in a twin cone convection blender to form a pre-mix.

10 The pre-mix, the first granulate, lemon flavour granulate and aspartame are then dry mixed in a conical screw mixer to produce a granulate which is then mixed for 9 minutes. Magnesium stearate is added and mixed for an additional 3 minutes to produce a second granulate comprising:

Calcium carbonate	1250 parts by weight
Sorbitol	390 parts by weight
Polyvinylpyrrolidone	36.4 parts by weight
20 Vitamin D ₃ 100 000 IU/g (100CWS from Roche)	4.4 parts by weight
Lemon flavour (in dehydrated glucose syrup)	50.7 parts by weight
Aspartame	1 part by weight
25 Magnesium stearate	6 part by weight

This mixture is then tableted to produce biconvex tablets of 16mm diameter containing 1250 mg calcium carbonate.

The characteristics of the tablets are as follows:

30 **Breaking strength:** The chewable tablet has a normal biconvex shape and a diameter of 16 mm. The tablet initially has a breaking strength of 6 to 7.5 kp which can increase to approximately 8 to 9 kp after 24 hour storage. This breaking strength gives a satisfactory chewability and at the same time resistance towards
35 handling and packaging into tablet bottles.

The initial breaking strength values may however

vary between 4.5 to 8.0 kp according to the size of the tablet (12-21 mm).

Friability: A breaking strength of 6 to 7.5 kp for a chewable tablet with a diameter of 16mm results in friability values of less than 1%. This low value for the friability ensures sufficient firmness with respect to handling and packaging.

Disintegration: A characteristic feature of this chewable tablet formulation is the very fast disintegrating time.

The disintegration time is typically between 3 and 6 min. It is also a characteristic feature of the tablet that it disintegrates into the primary crystals of calcium carbonate which ensures a rapid exposure of calcium carbonate for dissolution.

This is important for the in vivo dissolution of calcium carbonate in the acidic gastric medium in the stomach and the subsequent absorption of calcium in the gastrointestinal tract.

Porosity: The tablet has a characteristic porosity of 25-30%. The porosity is determined by both mercury intrusion porosimetry and helium adsorption as described above. Both techniques gave porosity values in the range 25-30% for the tablet.

Dissolution: The dissolution rate is typically quick with 90% elemental calcium being dissolved within 10 min in 900 ml of 0.1 N HCl at 37°C (Ph. Eur., rotating paddle at 50 RPM).

EXAMPLE 3

Lozenge to be sucked

Using a process analogous to that of Examples 1 and 2 lozenges are prepared with the following composition:

Calcium granulate:

Calcium carbonate (Scoralite 1B): 1250 mg

	Xylitol (CM50):	390 mg
	Polyvinylpyrrolidone (Kollidon K 30):	36.40 mg
	Vitamin D ₃ 100 000 IU/g (100 CWS from Roche):	4.4 mg
	Lemon flavor:	50.7 mg
5	Anhydrous citric acid:	8.0 mg
	Aspartame:	1.0 mg
	Magnesium stearate:	6.0 mg
		<hr/>
10	Sum tablet weight:	1747 mg
		<hr/>

EXAMPLE 4

Sachet product to be dispersed in a glass of water

Using a process analogous to that of Examples 1 and 2 but with sorbitol replaced by anhydrous citric acid, sachets are prepared with the following granulate contents:

Calcium granulate:

20	Calcium carbonate (Scoralite 1A):	1250 mg
	Citric acid, anhydrous (powder quality)	2150 mg
	Polyvinylpyrrolidone (Kollidon VA 64 or 90F):	36.60 mg
25	Vitamin D ₃ 100 000 IU/g (100 CWS from Roche):	4.4 mg
	Lemon flavor:	300 mg
	Aspartame:	15.0 mg
	Acesulfam K:	<u>14.0 mg</u>
30	Sum sachet contents weight:	3770 mg
		<hr/>

EXAMPLE 5

Granulate to be dispensed from a granulate dispensing unit

This product may be used as a food additive or as a functional food where the consumer takes a dosage

equivalent to 500-1000 mg of elemental calcium and uses this as a supplement in daily food products, such as for example breakfast cereals and fruit juices. The granulate is produced by a process analogous to that of Examples 1 and 2 with the following composition:

Calcium granulate:

Calcium carbonate (Scoralite 1A+1B):	1250 mg
Xylitol (CM 50):	390 mg
Polyvinylpyrrolidone (Kollidon VA 64):	<u>36 mg</u>
Granulate weight per 500 mg Ca ²⁺ :	<u>1676 mg</u>

In this Example, polyvinylpyrrolidone may be replaced by inulin (e.g. Raftiline ST), 36.60 mg. Additional inulin or oligofructose may be added to bring the total oligosaccharide content to 1 to 5 g per dosage.

EXAMPLE 6

Effervescent tablet to be dispersed in a glass of water

Using a process analogous to that of Examples 1 and 2, effervescent tablets are prepared with the following composition:

Calcium granulate:

Calcium carbonate (Scoralite 1A+1B):	1250 mg
Citric acid, anhydrous (powder quality)	2150 mg
Polyvinylpyrrolidone (Kollidon VA 64 or 90F):	36.60 mg
Vitamin D ₃ 100 000 IU/g (100 CWS from Roche):	4.4 mg
Lemon flavor:	300 mg
Aspartame:	15.0 mg
Acesulfam K:	15.0 mg
Sodium stearate fumarate:	19.0 mg

Sum tablet weight:	<u>3790 mg</u>
--------------------	----------------

In this Example, aspartame and acesulfam K may be partially or totally replaced by inulin or oligofructose with these providing 1 to 4 oligosaccharide per tablet.

5 **EXAMPLE 7**

Calcium carbonate grades

 Samples of Scoralite 1B, Scoralite 1A, Super Purity
10 CaCO₃, Medicinal Heavy CaCO₃, Pharmacarb LL and Merck
 2064 were investigated using a scanning electron
 microscope (SEM). SEM pictures of these grades of
 calcium carbonate are presented in Figures 1 to 6
 respectively of the accompanying drawings.

 Granulates made analogously to Example 1 using
15 Scoralite 1B and Super Purity CaCO₃ were also
 investigated by SEM and SEM pictures of these granulates
 at lower (A) and higher (B) magnifications are presented
 in Figures 7 and 8 of the accompanying drawings. The
20 pictures of the two granulates clearly show their high
 degree of porosity, a property which is important for
 the fast disintegration/dissolution of tablets made
 therefrom. Moreover, this high degree of porosity is
 important for the sensory properties such as chewability
25 and avoidance of sticking to the teeth during
 mastication.

EXAMPLES 8 TO 12

 Analogously to Examples 1 and 2, chewable tablets
30 and lozenges are prepared with the compositions set out
 in Table 1 below. The difference between a chewable
 tablet and a lozenge is simply in crushing strength or
 hardness, the lozenge being more forceably compressed so
 that it can be sucked and will last longer in the mouth.

35 The concentration of the binder in the aqueous
 granulation liquid and the granulation spray rate are
 adjusted in Examples 9 to 12 as follows:

Example 9: 20% maltodextrin solution, spray rate 31 g/min

Example 10: 15% inulin solution, spray rate 28 g/min.

5 Example 11: 15% inulin solution, spray rate 31 g/min.

Example 12: 28% PVP solution, spray rate 31 g/min.

10

15

20

25

30

Example Number	8	9	10	11	12
Ingredients in calcium granulate					
CaCO ₃ ¹	1250 mg	1250 mg	1250 mg	1250 mg	1250 mg
Isoflavone extract ²	-	-	-	-	62.5 mg
Xylitol ³	390 mg	-	-	-	389 mg
Sucrose ⁴	-	391 mg	-	-	-
Inulin ⁵	-	-	390 mg	-	-
Isomalt ⁶	-	-	-	390 mg	-
Polyvinyl-pyrrolidone VA64	36.40 mg	-	-	-	45.50 mg
Inulin ⁵	-	-	24.00 mg	24.00 mg	-
Maltodextrin ⁷	-	31.00 mg	-	-	-
Remaining Ingredients					
Vitamin D ₃ ⁸	4.4 mg	4.4 mg	4.4 mg	4.4 mg	4.4 mg
Lemon Flavour	53.2 mg	52.6 mg	52.6 mg	52.6 mg	52.6 mg
Anhydrous Citric Acid	8.0 mg	-	-	-	-
Malic Acid	-	8.0 mg	8.0 mg	8.0 mg	8.0 mg
Aspartame	-	-	1.0 mg	1.0 mg	-
Magnesium Stearate	8.0 mg	8.0 mg	8.0 mg	8.0 mg	8.0 mg
Tablet Weight	1750 mg	1745 mg	1738 mg	1738 mg	1820 mg

¹ Scoralite 1A + 1B

⁵ Raftiline ST

² Novasoy 400

⁶ Isomalt PF

³ CM 50

⁷ Lycatab DSH

⁴ Tate & Lyle

⁸ 100 CWS

5

In Examples 10 and 11, additional oligosaccharide (e.g. inulin or oligofructose) may be added to bring the oligosaccharide content to 1 to 5 g per dosage.

10

EXAMPLE 13

Calcium Carbonate Characteristics

15

20

Different samples (lots) of Scoralite 1B and Scoralite 1A + 1B were investigated for particle size (using Malvern Particle size analysis performed on a Malvern Mastersizer S long bench apparatus and a Malvern Mastersizer 2000), specific surface area (BET analysis by nitrogen adsorption performed on a Sartorius micro balance) and apparent bulk density (using apparent bulk density before settling (poured density) according to Ph. Eur., 3rd Edition, 1977). The values determined were as follows:

25

30

Scoralite Sample	1B	1B	1B	1A+1B	1A+1B	1A+1B
Apparent bulk density (g/mL)	1.09	1.04	1.02	0.95	0.99	0.89
D(v,0.5) µm	15.1	14.7	15.9	13.3	13.7	11.8
D(v,0.1) µm	8.8	8.7	8.1	6.3	6.5	3.9
D(v,0.9) µm	24.3	23.4	27.8	23.5	24.2	23.0
Specific surface area (m ² /g)	0.5	0.5	0.5	0.4	0.5	0.7

Claims:

1. A process for the preparation of an orally administrable calcium composition, said process comprising the steps of:

(i) obtaining a physiologically tolerable particulate calcium compound having a mean particle size in the range 3 to 40 μ m, having a crystalline structure and having a surface area of 0.1 to 1.2 m²/g;

(ii) mixing said calcium compound with a water-soluble diluent and an aqueous solution of a water soluble binder in a fluid bed granulation apparatus and drying the resulting mixture to produce a first granulate;

(iii) optionally mixing said first granulate with one or more further components to produce a second granulate; and

(iv) optionally compressing said first or second granulate to form tablets.

2. A process as claimed in claim 1 wherein said calcium compound is selected from calcium carbonate, calcium lactate, calcium gluconate, calcium citrate, calcium glycerophosphate, calcium phosphate, calcium hydrogen phosphate, calcium glucuronate, calcium aspartate, calcium glucoheptonate and mixtures of two or more thereof.

3. A process as claimed in claim 1 wherein said calcium compound is calcium carbonate.

4. A process as claimed in any one of claims 1 to 3 wherein said calcium compound makes up 68 to 80% wt. of said first granulate.

5. A process as claimed in any one of claims 1 to 4 wherein said calcium compound makes up 60 to 95% wt. of

said second granulate.

5 6. A process as claimed in any one of claims 1 to 5 wherein in step (i) the same material is used as said diluent and as said binder.

10 7. A process as claimed in any one of claims 1 to 6 wherein said water-soluble diluent comprises at least one sweetener.

15 8. A process as claimed in claim 7 wherein said sweetener is selected from sorbitol, xylitol, isomalt, mannitol, sucrose, fructose, maltodextrin, inulin and oligofructose.

20 9. A process as claimed in any one of claims 1 to 8 wherein said water-soluble diluent makes up 70 to 96% wt. of the total weight of said water-soluble diluent and said water-soluble binder in said first granulate.

25 10. A process as claimed in any one of claims 1 to 9 wherein said water-soluble binder is selected from celluloses, polysaccharides, maltodextrin, inulin and polyvinylpyrrolidone.

30 11. A process as claimed in any one of claims 1 to 10 wherein said water-soluble binder is a polyvinylpyrrolidone.

35 12. A process as claimed in any of claims 1 to 11 wherein said first granulate has a particle size distribution of $D(V, 0.1) = 15-21 \mu\text{m}$, $D(V, 0.5) = 70-120 \mu\text{m}$ and $D(V, 0.9) = 190-330 \mu\text{m}$.

13. A process as claimed in any one of claims 1 to 12 wherein a said further component is mixed with said first granulate, said further component being selected

from: vitamin B₆, vitamin K, vitamin C, vitamin D, isoflavones, inulin, and oligofructose and mixtures of two or more thereof.

5 14. A process as claimed in any one of claims 1 to 13 wherein in step (ii) said calcium compound is also mixed with isoflavones.

10 15. A granulate comprising a fluid bed granulation granulate product of a physiologically tolerable calcium compound, a water-soluble binder and a water-soluble diluent, said calcium compound having a mean particle size in the range 3 to 40 μ m, having a crystalline structure and having a surface area of 0.1 to 1.2 m²/g.

15 16. A granulate as claimed in claim 15 further comprising a lubricant.

20 17. A granulate as claimed in either of claims 15 and 16 wherein said calcium compound is selected from calcium carbonate, calcium lactate, calcium gluconate, calcium citrate, calcium glycerophosphate, calcium phosphate, calcium hydrogen phosphate, calcium glucuronate, calcium aspartate, calcium glucoheptonate
25 and mixtures of two or more thereof.

30 18. A granulate as claimed in any one of claims 15 to 17 said diluent is a sweetener selected from sorbitol, xylitol, mannitol, sucrose, fructose, maltodextrin, inulin and oligofructose.

35 19. A granulate as claimed in any one of claims 15 to 18 wherein said water-soluble binder is selected from celluloses, polysaccharides, maltodextrin, inulin and polyvinylpyrrolidone.

20. A granulate as claimed in any one of claims 15 to

19 comprising a further component selected from: vitamin B₆, vitamin K, vitamin C, vitamin D, isoflavones, inulin, and oligofructose and mixtures of two or more thereof.

- 5 21. A tablet comprising a compressed granulate as claimed in any one of claims 15 to 20 containing: calcium carbonate; vitamin D₃; a lubricant; citric acid; and an oligosaccharide.




FIG. 1
SCORALITE 1B




FIG. 2
SCORALITE 1A




FIG. 3


SUPER-PURITY CaCO_3 

FIG. 4

MEDICINAL HEAVY CaCO_3




FIG. 5
PHARMA CARB LL




FIG. 6
MERCK 2064




FIG. 7A
SCORALITE 1B




FIG. 7B
SCORALITE 1B

09/831553-410501




FIG. 8A


SUPER PURITY CaCO₃

FIG. 8B

SUPER PURITY CaCO₃

DECLARATION AND POWER OF ATTORNEY

For Utility or Design Application

As a below named inventor, I/we hereby declare that my/our residence, post office address and citizenship are as stated below next to my/our name.

I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed for and for which a patent is sought on the invention entitled:

PROCESS FOR PREPARING ORAL CALCIUM COMPOSITIONS

The specification of which:

☐ is attached hereto

OR

☒ was filed on May 11, 2001 as U.S. Application Serial No. 09/831,553 or PCT International No. _____ and was amended on May 11, 2001 (if applicable).

I/We hereby state that I/we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I/We acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I/We hereby claim foreign priority benefits under 35 U.S.C. 1.119(a)-(d) or 1.365(b) of any foreign application(s) for patent or inventor's certificate or 1.365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
Great Britain	9825033.5	13 November 1998	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. 1.119(e) of any United States provisional application(s) listed below:

Application Number	Date of Filing

I/We hereby claim the benefit under 35 U.S.C. 1.120 of any United States application(s) or 1.365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. 1.112, I/we acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status(Patented, Pending, Abandoned)
PCT/GB99/03666	05 November 1999	Completed

I/We hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith.

John W. Ryan, Reg. No. 33,771; Christopher T. McWhinney, Reg. No. 42,875; Jeremy K. McKown, Reg. No. 47,785; Anderson I. Chen, Reg. No. 44,436; Timothy B. Kang, Reg. No. 46,423; Ashok K. Mannava, Reg. No. 45,301; Bryan E. Webster, Reg. No. 47,214; Hyung Sohn, Reg. No. 44,346, Krishna Kalidindi, Reg. No. 41,461 and Parmita Ghosh, Reg. No. 42,806.

Please direct all correspondence to:

John W. Ryan
WILMER, CUTLER & PICKERING
2445 M Street, N.W.
Washington, DC 20037-1420

Please direct all telephone calls to:

Jeremy K. McKown (202) 663-6520

I/We hereby declare that all statements made herein of my/our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: <u>Jan Yngvar PIENE</u>	Inventor's Signature: <u>Jan Yngvar Piene</u>	Date: <u>27.09.01</u>
Residence: <u>UNDELSTAD TERR. 25B, 1387 ASKER</u> <u>Oslo, Norway</u> <u>NOX</u>		Citizenship: <u>Norway</u>
Post Office Address: <u>Nycomed Pharma AS, Drammensveien 852, 1372 Asker, Norway</u>		
Full Name of Second Inventor: <u>Dina Dogger SCHMIDT</u>	Inventor's Signature: <u>Dina D. Schmidt</u>	Date: <u>09.10.2001</u>
Residence: <u>ØVRE FRYØENDAL 8A, 1384 ASKER</u> <u>Oslo, Norway</u> <u>NOX</u>		Citizenship: <u>Norway</u>
Post Office Address: <u>Nycomed Pharma AS, Drammensveien 852, 1372 Asker, Norway</u>		
Full Name of Third Inventor:	Inventor's Signature:	Date:
Residence:	Citizenship:	
Post Office Address:		